Natera Inc at Barclays Global Healthcare Conference Transcript
Good afternoon, and this is Jack Meehan with the life science tools and diagnostics team here at Barclays. Thanks for joining our presentation now this afternoon with Natera and CFO, Mike Brophy. Mike is going to walk through some slides, and appreciate you joining us in the new virtual format.
And Mike, I'll hand it over to you.
Awesome. Thanks, Jack. So I hope everyone can see the slides. I'm just going to kind of just verbally kind of call out what slide I'm on as I go through this.
So maybe before jumping in, just a quick summary for those of you that are new to Natera, a public company, ticker NTRA. It's about $2 billion to $3 billion market cap company, depending on the [day] and the coronavirus situation. The core products are reproductive health diagnostics. So we are the market leader in what's called noninvasive prenatal testing, which is a blood draw from mom early in the pregnancy, screen the fetus for a range
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
